Centinel Spine has announced the first implantation of its prodisc C Vivo cervical total disc replacement (TDR) product in the Western US. The procedure was undertaken by Alexandre Rasouli of Rasouli Spine (Beverly Hills, USA).
Earlier this year, in July 2022, the company received US Food and Drug Administration approval for one-level indications for prodisc C Vivo, prodisc C SK, and prodisc C Nova. According to Centinel Spine, this mean the company now has the broadest offering of cervical TDR solutions in the world to address surgeon preference and individual patient anatomy.
“The prodisc portfolio in general has a long history of clinical excellence, utilising a proven mechanism of motion combined with established materials,” said Rasouli. “The prodisc C Vivo system was extremely easy to use and combines well-designed instruments along with a streamlined technique. This system will be a valuable treatment option for my patients, especially in the outpatient setting.”
Centinel Spine CEO, Steve Murray, added: “We are pleased that leading spine surgeons, like Alexandre Rasouli, are choosing to treat patients with prodisc C Vivo. The anatomic endplate designs of the entire prodisc cervical portfolio provide options for surgeons to choose the best disc for each patient according to their anatomy. The prodisc C Vivo implant is the newest option in Centinel Spine’s continued commitment to improving spine care.”
The prodisc C Vivo system has been in clinical use internationally since 2009 and, similar to all prodisc products, incorporates prodisc CORE technology.
